
    
      This is a phaseâ… sequential-group study of ascending single and multiple oral doses
      administered to subjects with HER2-Positive Advanced Breast Cancer. Each subject will receive
      a single dose of Hemay022, followed by a 1-week observation period, and then will receive
      Hemay022 administered once daily by mouth for 28 days. Each cycle consist of 28 days.
      Subjects will be enrolled in groups of 3 to 6. Depending on the safety and activity profile
      observed during the dose escalation phase, the dose selected for Part 2 may be adjusted. Part
      2 is an extension part of three dose groups.
    
  